EcoDrugPlus

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSPSNG00000007686
Gene Symbol: MET
3 Cross references
211 Possible Orthologues:

Mpl Proto-Oncogene, Thrombopoietin Receptor

Ensembl ID : ENSPSNG00000002348
Gene Symbol: MPL
1 Cross references
186 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSPSNG00000016673
Gene Symbol: MLST8
3 Cross references
201 Possible Orthologues:

Nad(P)h Quinone Dehydrogenase 1

Ensembl ID : ENSPSNG00000012659
Gene Symbol: NQO1
1 Cross references
195 Possible Orthologues:

Nadph Oxidase 4

Ensembl ID : ENSPSNG00000016374
Gene Symbol: NOX4
1 Cross references
151 Possible Orthologues:

Nfe2 Like Bzip Transcription Factor 2

Ensembl ID : ENSPSNG00000005384
Gene Symbol: NFE2L2
3 Cross references
216 Possible Orthologues:

Npc1 Like Intracellular Cholesterol Transporter 1

Ensembl ID : ENSPSNG00000009032
Gene Symbol: NPC1L1
3 Cross references
189 Possible Orthologues:

Pim-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSPSNG00000020661
Gene Symbol: PIM1
1 Cross references
244 Possible Orthologues:

Pim-2 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSPSNG00000021950
Gene Symbol: PIM2
3 Cross references
115 Possible Orthologues:

Pim-3 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSPSNG00000019628
Gene Symbol: PIM3
3 Cross references
217 Possible Orthologues:

Rar Related Orphan Receptor C

Ensembl ID : ENSPSNG00000000836
Gene Symbol: RORC
3 Cross references
382 Possible Orthologues:

Rela Proto-Oncogene, Nf-Kb Subunit

Ensembl ID : ENSPSNG00000010702
Gene Symbol: RELA
3 Cross references
199 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).